Abstract 248P
Background
Children receiving palliative care face unique physical and psychosocial needs. Parents may turn to complementary medicines (CM); however, related studies are limited. This study examined the pattern of CM use among pediatric patients with cancer and non-cancer conditions receiving palliative care.
Methods
Between April 2021 and June 2022, parents of patients (<19 years old) receiving palliative care were recruited from 3 hospitals in Hong Kong. They completed a structured survey on sociodemographic data, CM use, and the child’s symptom burden (Rotterdam Symptoms Checklist). Clinical data were collected from health records. Differences in characteristics were compared among CM users (with cancer or non-cancer conditions) and non-users.
Results
We recruited 61 patients (60.7% male; mean age=10.4 years). Overall, 68.9% reported CM use, most commonly Chinese herbal medicine (39.3%) and massage/TuiNa (34.4%). Among the 24 patients with cancer, 62.5% were CM users; they were older at cancer diagnosis than non-users (p<0.001). Non-oral CM approaches, especially acupuncture, were less popular among patients with cancer than non-cancer patients (29.2% vs 64.9%, p=0.01). Among CM users, patients with cancer had higher physical symptom distress than non-cancer users (22.0 vs 17.3, p<0.01). More parents of children with cancer consulted their doctors before using CM than non-cancer users (73.3% vs 33.3% p=0.03), and considered CM to be effective in relieving nausea, vomiting and indigestion symptoms (p<0.05). Most parents (73%) spent ≥USD 130 on CM monthly. Among cancer patients, the most common reason for not using CM was the lack of information (55.6%). Multivariable analyses showed that older parents (aOR=1.15, 95%CI=1.02-1.31) were more likely to use CM, while children who received bone marrow transplant were less likely to use CM (aOR=0.16, 95%CI=0.03-0.73). Most parents (82.5%) supported CM integration, especially Chinese medicine and acupuncture, into palliative care service.
Conclusions
Two-third of surveyed pediatric patients with cancer receiving palliative care used CM regularly. Future work should explore integrating CM approaches into palliative programs for symptom management and psychological support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03